Clinical Research Directory
Browse clinical research sites, groups, and studies.
Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation
Sponsor: University Hospital, Basel, Switzerland
Summary
This study investigates the safety and tolerability of Nintedanib in patients with bronchiolitis obliterans syndrome (BOS) following allogeneic hematopoietic cell transplantation. All study patients with BOS will be treated with the study drug Nintedanib (300 mg/day) as an add-on therapy to their basic immunosuppressive treatment over a 12-months treatment period.
Official title: Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation (HSCT)- a Multicentre Phase II Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2019-03-20
Completion Date
2026-12
Last Updated
2025-12-15
Healthy Volunteers
No
Interventions
Nintedanib
Nintedanib 150 mg Kps bid (oral); in order to manage adverse events, the dose of Nintedanib may be reduced from 150 mg twice daily to 100 mg twice daily
Locations (3)
King Faisal Specialist Hospital & Research Centre
Riyadh, Saudi Arabia
Clinic of Hematology, University Hospital Basel
Basel, Switzerland
Clinic of Respiratory Medicine, University Hospital Basel
Basel, Switzerland